Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.
Also called NCT03175367
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 272 participants
- Sponsor
- Registry
-
NCT03175367 -
2017-001508-31
-
- Other papers using this trial's data
- Evinacumab in Patients with Refractory Hypercholesterolemia
- Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Canada, Czechia, Denmark, France, Israel, Italy, Japan, Jordan, Netherlands, New Zealand, Norway, Poland, Russia, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03175367. Randomized; triple masking; primary purpose treatment. Start 2017-11-10 (actual); primary completion 2020-05-22 (actual). Results posted on 2023-02-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Evinacumab
- Intervention (Drug)
- Matching placebo
- Intervention (Other)
- Background Lipid Modifying Therapy (LMT)
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct03175367- Content hash
30119def6b59fa78aad70a1a29cb5bdba92848a7b7bd04b8887aae810c6e16d3